OraSure Tech (OSUR) Settles Patent Infringement Suit with Inverness (IMA), Inverness Switzerland, and Church & Dwight (CHD)

November 19, 2009 7:24 AM EST

OraSure Technologies, Inc. (NASDAQ: OSUR) today announced the settlement of the patent infringement lawsuit filed against OraSure by Inverness Medical Innovations, Inc. (NYSE: IMA), Inverness Medical Switzerland GmbH and Church & Dwight, Co., Inc. (NYSE: CHD).

Under the settlement, OraSure has agreed to pay Inverness a sum of $3,000,000 in cash and Inverness has agreed to grant OraSure certain licenses to its lateral flow patents. In addition, each party has received distribution rights to certain products supplied by the other party.

Terms of the settlement include the following:

• The grant to OraSure of a worldwide, non-exclusive, royalty-bearing, lateral flow patent license (subject to a royalty-free period) for the OraQuick(R) HIV-1/2 test and other visually-read HIV lateral flow products in the professional market;
  
  
• The grant to OraSure of a worldwide, non-exclusive, royalty-bearing, lateral flow patent license (subject to a royalty-free period) for the OraQuick(R) HCV test and other visually read HCV lateral flow products in the professional market;
  
  
• The grant to OraSure of a worldwide, non-exclusive, royalty-bearing, license to Inverness lateral flow patents for visually-read products for the detection of certain infectious diseases, metabolic disorders, cancer and autoimmune disorders;
  
  
  
• The grant to OraSure of non-exclusive rights to distribute in the United States as private label products certain rapid, point-of-care, flu, strep, drugs of abuse and pregnancy tests manufactured by Inverness;
  
  
• A right of first negotiation during the 120-day period following the settlement effective date for OraSure to negotiate the terms for the marketing and distribution of the OraQuick(R) HIV-1/2 test on an exclusive basis in the over-the-counter markets worldwide with the consumer diagnostics joint venture between Proctor & Gamble (NYSE:PG) and Inverness; and
  
  
• The grant to Inverness of exclusive distribution rights to the OraQuick(R) HCV test in the employee health services and home healthcare markets and in acute care clinics located in pharmacies and other mass retail outlets in the United States.

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?